Brought to you by 
Sarepta options CMT gene therapy candidate from NCH
02 Nov 2018
Executive Summary
Sarepta Therapeutics Inc. gained an exclusive option to Nationwide Children's Hospital's neurotrophin 3 (NT-3) gene therapy candidate for Charcot-Marie-Tooth (CMT) disease, a group of rare, inherited, degenerative motor and sensory neuropathies that affects the peripheral nerves and can lead to muscle wasting and numbness.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sarepta options CMT gene therapy candidate from NCH
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice